Abstract:Dysregulated neutrophil activation contributes to the pathogenesis of autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Neutrophil-derived reactive oxygen species (ROS) and granule proteases are implicated in damage to and destruction of host tissues in both conditions (cartilage in RA, vascular tissue in SLE) and also in the pathogenic post-translational modification of DNA and proteins. Neutrophil-derived cytokines and chemokines regulate both the innate and adaptive immune responses in RA and SLE, and neutrophil extracellular traps (NETs) expose nuclear neoepitopes (citrullinated proteins in RA, double-stranded DNA and nuclear proteins in SLE) to the immune system, initiating the production of auto-antibodies (ACPA in RA, anti-dsDNA and anti-acetylated/methylated histones in SLE). Neutrophil apoptosis is dysregulated in both conditions: in RA, delayed apoptosis within synovial joints contributes to chronic inflammation, immune cell recruitment and prolonged release of proteolytic enzymes, whereas in SLE enhanced apoptosis leads to increased apoptotic burden associated with development of anti-nuclear auto-antibodies. An unbalanced energy metabolism in SLE and RA neutrophils contributes to the pathology of both diseases; increased hypoxia and glycolysis in RA drives neutrophil activation and NET production, whereas decreased redox capacity increases ROS-mediated damage in SLE. Neutrophil low-density granulocytes (LDGs), present in high numbers in the blood of both RA and SLE patients, have opposing phenotypes contributing to clinical manifestations of each disease. In this review we will describe the complex and contrasting phenotype of neutrophils and LDGs in RA and SLE and discuss their discrete roles in the pathogenesis of each condition. We will also review our current understanding of transcriptomic and metabolomic regulation of neutrophil phenotype in RA and SLE and discuss opportunities for therapeutic targeting of neutrophil activation in inflammatory auto-immune disease.

Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets

Neutrophil Function in an Inflammatory Milieu of Rheumatoid Arthritis

Nutrients and Rheumatoid Arthritis: from the Perspective of Neutrophils

Neutrophils in chronic inflammatory diseases

Neutrophil function in inflammation and inflammatory diseases

Crossroads: Pathogenic role and therapeutic targets of neutrophil extracellular traps in rheumatoid arthritis

Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O.

The emerging role of neutrophil extracellular traps in the progression of rheumatoid arthritis

Enhanced Neutrophil Autophagy and Increased Concentrations of IL-6, IL-8, IL-10 and MCP-1 in Rheumatoid Arthritis.

The role of neutrophils in rheumatic disease-associated vascular inflammation

Complexity of the neutrophil transcriptome in early and severe rheumatoid arthritis. A role for microRNAs?

The emerging role of neutrophils in autoimmune‐associated disorders: effector, predictor, and therapeutic targets

Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective

Target Role of Monocytes as Key Cells of Innate Immunity in Rheumatoid Arthritis

Advancements in rheumatoid arthritis therapy: a journey from conventional therapy to precision medicine via nanoparticles targeting immune cells

CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis

Neutrophils with Low Production of Reactive Oxygen Species Are Activated During Immune Priming and Promote Development of Arthritis.

Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies

The role of neutrophil extracellular traps in inflammatory rheumatic diseases

Targeting Pathways and Integrated Approaches to Treat Rheumatoid Arthritis

The monocyte-to-osteoclast transition in rheumatoid arthritis: Recent findings